A rare case of orbital hodgkin lymphoma demonstrating therapeutic response to a novel systemic medication.
Orbital Hodgkin lymphoma is infrequent, representing less than 1% of adult orbital malignancies. It is typically seen in the setting of terminally advanced systemic disease. This case highlights orbital, head, and neck disease in a systemically stable individual treated with the novel anti-CD30 monoclonal antibody brentuximab vedotin.
a Ophthalmology Residency Program , Wills Eye Hospital, Thomas Jefferson University Hospital , Philadelphia , Pennsylvania , USA.
Brynn N
BN
Wajda
b Department of Oculoplastic and Orbital Surgery , Wills Eye Hospital , Philadelphia , Pennsylvania , USA.
Michael P
MP
Rabinowitz
D000328:Adult; D014408:Biomarkers, Tumor / Q000378:metabolism; D000079963:Brentuximab Vedotin; D006689:Hodgkin Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D008297:Male; D009918:Orbital Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism
D014408:Biomarkers, Tumor; D018796:Immunoconjugates; D000079963:Brentuximab Vedotin
Brentuximab; Hodgkin; lymphoma; orbit